A. Boucly, J. Weatherald, L. Savale, X. Jais, V. Cottin et al.,

P. Groote, M. Jevnikar, E. Bergot, A. Chaouat, C. Chabanne et al., Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension, Eur Respir J, vol.50, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01757586

T. Bertero, W. M. Oldham, K. A. Cottrill, S. Pisano, R. R. Vanderpool et al., Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension, J Clin Invest, vol.126, pp.3313-3335, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02479282

A. Huertas, L. Tu, and C. Guignabert, New targets for pulmonary arterial hypertension: going beyond the currently targeted three pathways, Curr Opin Pulm Med, vol.23, pp.377-385, 2017.

J. Avouac, C. Guignabert, A. M. Hoffmann-vold, B. Ruiz, P. Dorfmuller et al., Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis, Arthritis Rheumatol, vol.69, pp.2209-2221, 2017.

C. Guignabert, L. Tu, B. Girerd, N. Ricard, A. Huertas et al., New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication, Chest, vol.147, pp.529-537, 2015.

K. Maruyama, C. L. Ye, M. Woo, H. Venkatacharya, L. D. Lines et al., Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity, Am J Physiol, vol.261, pp.1716-1726, 1991.

K. N. Cowan, A. Heilbut, T. Humpl, C. Lam, S. Ito et al., Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor, Nature medicine, vol.6, pp.698-702, 2000.

S. H. Zaidi, X. M. You, S. Ciura, M. Husain, and M. Rabinovitch, Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension, Circulation, vol.105, pp.516-521, 2002.

R. Ilkiw, L. Todorovich-hunter, K. Maruyama, J. Shin, and M. Rabinovitch, , 1989.

, SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral arteries, suggesting a mechanism of monocrotaline-induced pulmonary hypertension in rats, Circulation research, vol.64, pp.814-825

A. Vieillard-baron, E. Frisdal, B. Raffestin, A. H. Baker, S. Eddahibi et al., Inhibition of matrix metalloproteinases by lung TIMP-1, 2003.

, gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats, Human gene therapy, vol.14, pp.861-869

P. W. Noble, C. Albera, W. Z. Bradford, U. Costabel, R. M. Du-bois et al., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials, Eur Respir J, vol.47, pp.243-253, 2016.

P. W. Noble, C. Albera, W. Z. Bradford, U. Costabel, M. K. Glassberg et al., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, vol.377, pp.1760-1769, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00873255

T. E. King, . Jr, W. Z. Bradford, S. Castro-bernardini, E. A. Fagan et al., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med, vol.370, pp.2083-2092, 2014.

C. J. Schaefer, D. W. Ruhrmund, L. Pan, S. D. Seiwert, and K. Kossen, , 2011.

, Antifibrotic activities of pirfenidone in animal models, Eur Respir Rev, vol.20, pp.85-97

C. Guignabert, C. Phan, A. Seferian, A. Huertas, L. Tu et al., Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension, J Clin Invest, vol.126, pp.3207-3218, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02579754

Y. Tamura, C. Phan, L. Tu, M. Le-hiress, R. Thuillet et al., Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension, J Clin Invest, vol.128, pp.1956-1970, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02580448

L. Tu, F. S. De-man, B. Girerd, A. Huertas, M. C. Chaumais et al., A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents, Am J Respir Crit Care Med, vol.186, pp.666-676, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00905191

A. Huertas, L. Tu, R. Thuillet, M. Le-hiress, C. Phan et al., Leptin signalling system as a target for pulmonary arterial hypertension therapy, Eur Respir J, vol.45, pp.1066-1080, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02579431

L. Tu, L. Dewachter, B. Gore, E. Fadel, P. Dartevelle et al., Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension, Am J Respir Cell Mol Biol, vol.45, pp.311-322, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00579959

R. Savai, H. M. Al-tamari, D. Sedding, B. Kojonazarov, C. Muecke et al., Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension, Nat Med, vol.20, pp.1289-1300, 2014.

R. Vivar, C. Humeres, C. Munoz, P. Boza, S. Bolivar et al., FoxO1 mediates TGF-beta1-dependent cardiac myofibroblast differentiation, Biochim Biophys Acta, vol.1863, pp.128-138, 2016.

H. Yadav, S. Devalaraja, S. T. Chung, and S. G. Rane, TGF-beta1/Smad3 Pathway Targets PP2A-AMPK-FoxO1 Signaling to Regulate Hepatic Gluconeogenesis, J Biol Chem, vol.292, pp.3420-3432, 2017.

H. M. Al-tamari, S. Dabral, A. Schmall, P. Sarvari, C. Ruppert et al., FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis, EMBO Mol Med, vol.10, pp.276-293, 2018.

B. Egemnazarov, S. Crnkovic, B. M. Nagy, H. Olschewski, and G. Kwapiszewska, Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions, Matrix Biol, pp.507-521, 2018.

M. J. Golob, Z. Wang, A. J. Prostrollo, T. A. Hacker, and N. C. Chesler, Limiting collagen turnover via collagenase-resistance attenuates right ventricular dysfunction and fibrosis in pulmonary arterial hypertension, 2016.

Y. Wang, Y. Wu, J. Chen, S. Zhao, L. et al., Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation, Cardiology, vol.126, pp.1-11, 2013.

K. W. Lee, T. H. Everett, D. Rahmutula, J. M. Guerra, E. Wilson et al., Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure, Circulation, vol.114, pp.1703-1712, 2006.

D. T. Nguyen, C. Ding, E. Wilson, G. M. Marcus, and J. E. Olgin, , 2010.

, Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias, Heart Rhythm, vol.7, pp.1438-1445

S. Mirkovic, A. M. Seymour, A. Fenning, A. Strachan, S. B. Margolin et al.,

M. Brown and L. , Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats, Br J Pharmacol, vol.135, pp.961-968, 2002.

M. Yoshida, K. Hata, R. Takashima, K. Ono, E. Nakamura et al., The transcription factor Foxc1 is necessary for Ihh-Gli2-regulated endochondral ossification, Nat Commun, vol.6, p.6653, 2015.

P. Bonniaud, A. Fabre, N. Frossard, C. Guignabert, M. Inman et al.,

T. Maes, W. Shi, M. Stampfli, S. Uhlig, E. White et al.,

A. Magnan, B. Maitre, U. A. Maus, P. Reinhold, J. H. Vernooy et al., Optimising experimental research in respiratory diseases: an ERS statement, Eur Respir J, p.51, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01996906

G. Simonneau, M. A. Gatzoulis, I. Adatia, D. Celermajer, C. Denton et al.,

H. Olschewski, I. M. Robbins, and R. Souza, Updated clinical classification of pulmonary hypertension, J Am Coll Cardiol, vol.62, pp.34-41, 2013.

M. J. Richter, J. Ewert, F. Grimminger, H. A. Ghofrani, B. Kojonazarov et al., Nintedanib in Severe Pulmonary Arterial Hypertension, Am J Respir Crit Care Med, 2018.